drugset / Trial / NCT00658749

A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma

NCT00658749 ↗

Phase 1 Completed 80 enrolled Altair Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase one study to evaluate the safety, tolerability, and bioavailability of nebulized AIR645.

Timeline

Start
2008-04
Primary completion
2009-04
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AIR645 Unknown — Other

Indications